<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04784533</url>
  </required_header>
  <id_info>
    <org_study_id>CP543.2004</org_study_id>
    <nct_id>NCT04784533</nct_id>
  </id_info>
  <brief_title>A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata</brief_title>
  <official_title>A Study to Evaluate Maintenance of Hair Regrowth Following Dose Reduction of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concert Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Concert Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two part, double-blind, randomized, multicenter study to evaluate the regrowth of&#xD;
      hair with CTP-543 and subsequent durability of that regrowth following dose reduction in&#xD;
      adult patients with moderate to severe alopecia areata.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients achieving loss of maintenance criteria defined by SALT following dose reduction</measure>
    <time_frame>24 weeks</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients achieving loss of maintenance criteria defined by SALT following drug discontinuation</measure>
    <time_frame>24 weeks</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients by dose group achieving restoration of regrowth</measure>
    <time_frame>24 weeks</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving loss of maintenance criteria following dose reduction</measure>
    <time_frame>Weeks 4, 8, 12, 16, and 20</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving loss of maintenance criteria following drug discontinuation</measure>
    <time_frame>Weeks 4, 8, 12, 16, and 20</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, Period 1: Percentage of responders (defined as &quot;satisfied&quot; or &quot;very satisfied&quot;) on the Hair Satisfaction Patient Reported Outcome (SPRO) scale</measure>
    <time_frame>Weeks 12, 16, 20, and 24</time_frame>
    <description>SPRO is a questionnaire answered by the patient designed to measure how satisfied alopecia areata patients are with their hair at the time of the assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, Period 1: Percentage of patients achieving an absolute SALT score â‰¤20</measure>
    <time_frame>Weeks 8, 12, 16, 20, and 24</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, Period 1: Relative change in SALT scores from Baseline</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, and 24</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, Period 1: Percentage of responders (defined as &quot;much improved&quot; or &quot;very much improved&quot;) using the CGI-I</measure>
    <time_frame>Weeks 12, 16, 20, and 24</time_frame>
    <description>The Clinician Global Impression of Improvement (CGI-I) is a questionnaire that asks the clinician to evaluate the improvement or worsening of the patient's alopecia areata as compared to the start of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, Period 1: Percentage of responders (defined as &quot;much improved&quot; or &quot;very much improved&quot;) using the PGI-I</measure>
    <time_frame>Weeks 12, 16, 20, and 24</time_frame>
    <description>The Patient Global Impression of Improvement (PGI-I) is a self-administered questionnaire that asks the patient to evaluate the improvement or worsening of their alopecia areata as compared to the start of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, Period 1: Change from Baseline in the CGI-S</measure>
    <time_frame>Weeks 12, 16, 20, and 24</time_frame>
    <description>The Clinician Global Impression of Severity (CGI-S) is a questionnaire that asks the clinician to evaluate the severity of the patient's alopecia areata at the time of assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, Period 1: Change from Baseline in the PGI-S</measure>
    <time_frame>Weeks 12, 16, 20, and 24</time_frame>
    <description>The Patient Global Impression of Severity (PGI-S) is a self-administered questionnaire that asks the patient to evaluate the severity of their alopecia areata at the time of assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, Period 1: Change from Baseline on the individual items of the Hair Quality Patient Reported Outcome (QPRO) scale</measure>
    <time_frame>Weeks 12, 16, 20, and 24</time_frame>
    <description>The QPRO questionnaire provides additional details on key attributes of hair and helps provide context to the SPRO response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, Period 1: Percentage of patients achieving the restoration of regrowth</measure>
    <time_frame>Weeks 4, 8, 12, 16, and 20 of re-treatment</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, Period 1: Relative change in SALT scores from Part B Baseline</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, and 24 of re-treatment</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>72 weeks</time_frame>
    <description>An adverse event is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Alopecia Areata</condition>
  <arm_group>
    <arm_group_label>Part A, Period 1 - Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mg BID CTP-543 for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Period 1 - High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 mg BID CTP-543 for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Period 2 - Dose reduction from low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose reduction for a maximum of 24 weeks for those previously receiving 8 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Period 2 - Drug discontinuation from low dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for a maximum of 24 weeks for those previously receiving 8 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Period 2 - Dose reduction from high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose reduction for a maximum of 24 weeks for those previously receiving 12 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Period 2 - Drug discontinuation from high dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for a maximum of 24 weeks for those previously receiving 12 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mg BID CTP-543 for a maximum of 24 weeks for those meeting loss of maintenance criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 mg BID CTP-543 for a maximum of 24 weeks for those meeting loss of maintenance criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTP-543</intervention_name>
    <description>Oral dosing</description>
    <arm_group_label>Part A, Period 1 - High dose</arm_group_label>
    <arm_group_label>Part A, Period 1 - Low dose</arm_group_label>
    <arm_group_label>Part A, Period 2 - Dose reduction from high dose</arm_group_label>
    <arm_group_label>Part A, Period 2 - Dose reduction from low dose</arm_group_label>
    <arm_group_label>Part B - High dose</arm_group_label>
    <arm_group_label>Part B - Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral dosing</description>
    <arm_group_label>Part A, Period 2 - Drug discontinuation from high dose</arm_group_label>
    <arm_group_label>Part A, Period 2 - Drug discontinuation from low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Definitive diagnosis of alopecia areata with a current episode of scalp hair loss&#xD;
             lasting at least 6 months and not exceeding 10 years at the time of Screening. Total&#xD;
             disease duration greater than 10 years is permitted.&#xD;
&#xD;
          -  At least 50% scalp hair loss, as defined by a SALT score â‰¥50, at Screening and&#xD;
             Baseline.&#xD;
&#xD;
          -  Willing to comply with the study visits and requirements of the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with other medications or agents within 1 month of Baseline or during the&#xD;
             study that may affect hair regrowth or immune response.&#xD;
&#xD;
          -  Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical&#xD;
             treatment to the scalp, significant trauma to the scalp, or other scalp condition that&#xD;
             may interfere with the SALT assessment, or untreated actinic keratosis anywhere on the&#xD;
             body at Screening and/or Baseline.&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive medications within 3 months of Screening or&#xD;
             during the study, or biologics within 6 months of Screening or during the study.&#xD;
&#xD;
          -  Females who are nursing, pregnant, or planning to become pregnant while in the study,&#xD;
             and for 30 days after last dose of study drug.&#xD;
&#xD;
          -  Clinically significant medical condition, psychiatric disease, or social condition, as&#xD;
             determined by the Investigator, that may unfavorably alter the risk-benefit of study&#xD;
             participation, adversely affect study compliance, or confound interpretation of study&#xD;
             results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Colleen E. Hamilton, MS</last_name>
    <phone>781-860-0045</phone>
    <email>AAclinicaltrial_inquiries@concertpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Total Skin and Beauty Dermatology Center, PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology and Plastic Surgery/CCT Research</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kern Research, Inc.</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hope Clinical Research</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Dermatology &amp; Clinical Research Institute</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quest Dermatology Research</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Palmtree Clinical Research, Inc.</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colorado Center for Dermatology and Skin Surgery</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colorado Medical Research Center, Inc.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale University Church Street Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skin Care Research, LLC</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skin Care Research, LLC</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DeNova Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center, PC</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DS Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Michigan Center for Research Company, LLC</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Department of Dermatology</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>New Brighton</city>
        <state>Minnesota</state>
        <zip>55112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skin Specialists, PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skin Laser and Surgery Specialists of New Jersey</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Darst Dermatology</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Carolina Dermatology Associates, PLLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bexley Dermatology Research</name>
      <address>
        <city>Bexley</city>
        <state>Ohio</state>
        <zip>43209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vital Prospects Clinical Research Institute, PC</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Dermatology</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Plymouth Meeting</name>
      <address>
        <city>Plymouth Meeting</city>
        <state>Pennsylvania</state>
        <zip>19462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PEAK Research, LLC</name>
      <address>
        <city>Upper Saint Clair</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of the Carolinas</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Treatment and Research Center, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research, Inc.</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Springville Dermatology/CCT Research</name>
      <address>
        <city>Springville</city>
        <state>Utah</state>
        <zip>84663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West End Dermatology Associates</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CTP-543</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

